Tarsus Pharmaceuticals Reports $162.1 Million Revenue in Q1 2026, Net Loss Improves to $7.0 Million

Tarsus Pharmaceuticals, Inc. reported significant financial performance for the first quarter of 2026, with total revenues reaching $162.1 million, a substantial increase from $78.3 million in the same period of 2025. This growth was primarily driven by product sales of $145.4 million from XDEMVY, an ophthalmic solution for Demodex blepharitis, which saw an 85% year-over-year increase. Additionally, the company recognized $16.7 million in license fees and collaboration revenue, attributed to a regulatory milestone achieved under its China Out-License agreement.

Operating expenses for the quarter totaled $168.2 million, up from $104.6 million in the prior year, reflecting increased costs in several areas. Research and development expenses rose to $22.4 million, compared to $14.4 million in the previous year, driven by higher personnel costs and milestone payments related to ongoing clinical trials. Selling, general, and administrative expenses also surged to $136.4 million, up from $85.0 million, largely due to expanded marketing efforts and increased personnel to support the commercialization of XDEMVY.

The company reported a net loss of $7.0 million for the first quarter of 2026, a notable improvement from a net loss of $25.1 million in the same quarter of 2025. This reduction in losses was attributed to the significant increase in revenues, which helped offset the rise in operating expenses. The loss per share for the quarter was $0.16, compared to $0.64 in the prior year.

Tarsus has made strategic advancements, including the successful launch of XDEMVY in August 2023, following FDA approval. The company is also progressing with its clinical pipeline, including ongoing trials for TP-04 and TP-05, which target ocular rosacea and Lyme disease prophylaxis, respectively. The company initiated a Phase 2 trial for TP-05 in March 2026, with topline results expected in the first half of 2027.

Looking ahead, Tarsus anticipates continued growth driven by the commercialization of XDEMVY and the advancement of its clinical programs. The company reported cash, cash equivalents, and marketable securities totaling $388.7 million as of March 31, 2026, which it believes will be sufficient to fund operations for at least the next twelve months. However, Tarsus acknowledges the potential need for additional capital to support its ongoing development and commercialization efforts, particularly as it expands its product pipeline and navigates the complexities of the biopharmaceutical market.